ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Label-free cell phenotypic profiling of sphingosine-1-phosphate receptor 1 and discovery of its agonist from natural products.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Sphingosine-1-phosphate receptor 1 (S1PR1) belonging to G protein-coupled receptors (GPCRs), plays a significant role in autoimmune diseases and cancer via regulating immune cell migration, vascular barrier function, and cell survival. Although four S1PR1 agonists have been clinically approved, their applications are limited by adverse effects, necessitating the discovery of novel S1PR1 agonists. In this study, we established a HEK293T-hS1PR1 high-throughput screening model for S1PR1 ligand discovery using dynamic mass redistribution (DMR) and fluorescent imaging plate reader (FLIPR) assays. Through structure-based virtual screening of anti-inflammatory compounds, we identified corylin, a natural compound derived from Psoralea corylifolia L., as a novel S1PR1 agonist. Corylin demonstrated micromolar-level agonistic activity with EC
Indexed as
Identifiers
42209736What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.